Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
Mohamed Mahmoud Marey,Mohamed Mohamed Belal,Abdelaziz A. Awad,Eslam Mohammed Rabea,Malak A. Hassan,Ahmed W. Abbas,Abdulqadir J. Nashwan
DOI: https://doi.org/10.1016/j.clinre.2024.102357
IF: 3.189
2024-05-01
Clinics and Research in Hepatology and Gastroenterology
Abstract:Background : Non-alcoholic steatohepatitis (NASH) is an advanced subtype of non-alcoholic fatty liver disease (NAFLD). NASH prevalence is increasing exponentially and carries a high risk for disease progression, cirrhosis, and liver-related mortality. Aldafermin, a fibroblast growth factor 19 (FGF19) analog, is one of the evolving therapeutic agents with the potential to regulate multiple pathways involved in the pathogenesis of NASH. We aimed to investigate the efficacy and safety of aldafermin in patients with NASH. Methods : PubMed, Scopus, Cochrane Library, and Web of Science were searched till November 2023 to identify eligible randomized controlled trials (RCTs). Continuous data were pooled as mean difference (MD), while dichotomous data were pooled as risk ratios (RR) with a 95% confidence interval. A subgroup meta-analysis was conducted to evaluate the efficacy of the two doses (1 mg and 3 mg) of aldafermin. Results : Four RCTs with a total of 491 patients were included. Aldafermin showed a dose-dependent improvement in the ≥30% reduction in the liver fat content (RR: 2.16, 95% CI [1.41 to 3.32]) and (RR: 5.00, 95% CI [1.34 to 18.64]), alanine aminotransferase levels (MD: -19.79, 95% CI [-30.28 to -9.3]) and (MD: -21.91, 95% CI [-29.62 to -14.21]), aspartate aminotransferase levels (MD: -11.79, 95% CI [-18.06 to -5.51]) and (MD: -13.9, 95% CI [-18.59 to -9.21]), and enhanced liver fibrosis score (ELF) (MD: -0.13, 95% CI [-0.29 to 0.02]) and (MD: -0.33, 95% CI [-0.50 to -0.17]), in the 1 mg and 3 mg subgroups respectively. No significant differences were detected in the aldafermin group regarding histologic endpoints, lipid profile, metabolic parameters, and overall adverse effects, except for the increased occurrence of diarrhea in the aldafermin 3 mg subgroup. Conclusion : Aldafermin is a promising well-tolerated therapeutic agent for NASH with evidence supporting its ability to reduce liver fat content, fibrosis serum biomarkers, and liver enzymes. However, its effectiveness in improving histologic fibrosis, while showing numerical trends, still lacks statistical significance. Larger and longer NASH trials are warranted to enhance the robustness of the evidence.
gastroenterology & hepatology